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Contrary to the standard of eliminating antimicrobial hits that collapse bacterial proton motive force (PMF), in
this issue ofChemistry and Biology, Farha and colleagues describe the value of screens to identify molecules
that dissipate PMF, yet are nonbacteriolytic and selectively toxic.The urgent need to discover and develop
novel antimicrobial agents is underscored
by the rapid spread of bacterial patho-
gens exhibiting resistance to most clas-
ses of clinically used antibiotics. Yet, the
indispensable bacterial membrane that
houses several essential proteins and
the prokaryotic respiratory chain remain
underexploited for discovering new anti-
biotics (Hurdle et al., 2011). It is well
accepted that newly discovered antimi-
crobial chemotypes should be efficacious
against multi-drug resistant organisms,
while avoiding cytotoxicity or adverse
toxicity in animals, to warrant progression
as clinical candidates (O’Neill and Cho-
pra, 2004). In this regard, chemical
libraries of natural and synthetic origins
have been extensively screened by aca-
demic groups and pharmaceutical com-
panies to find new antibiotic chemotypes.
Such screens routinely identify hits with
potent antibacterial activity but often
result in the disturbance of the functional
integrity and associated bioenergetics of
the prokaryotic membrane (Payne et al.,
2007). These hits include molecules that
inhibit the bacterial respiratory chain,
lyse or induce curvature of the cyto-
plasmic membrane, or possess a mode
of action that is challenging to elucidate,
such as molecules that co-interact with
the membrane and peptidoglycan com-ponents or membrane embedded pro-
teins (Figure 1) (Hurdle et al., 2011;
Pogliano et al., 2012). Many of these hits
contain lipophilic moieties and also cause
damage to mammalian membranes or
display cytotoxicity, making them unde-
sirable for progression. Therefore, a near
consensus has emerged in the antibiotic
discovery field that such molecules are
nuisances that should be removed early
in the drug discovery process to avoid
downstream toxicity problems in mam-
mals (O’Neill and Chopra, 2004; Payne
et al., 2007). Hence counter-screening
assays have been exploited to eliminate
hits disrupting the functional properties
of the membrane. Although it is certainly
pertinent to eliminate molecules that are
cytotoxic and cause leakage of the pro-
karyotic cytosol, which could induce
septicemia, it is now apparent that not
all molecules targeting the functional
properties of the bacterial membrane are
undesirable or even lack a therapeutic in-
dex for safe use in humans (Hurdle et al.,
2011). Indeed, within the last decade, we
have seen the clinical development of
the drugs daptomycin and telavancin,
whose potency in part arise from mem-
brane interaction; the ongoing clinical
development of membrane-active agents
such as HT61 and XF73 for nasal decolo-
nization of methicillin-resistant Staphylo-coccus aureus; and the emergence of
the respiratory chain as a leading drug
target in Mycobacterium tuberculosis
(Hurdle et al., 2011; Koul et al., 2011). As
demonstrated with daptomycin, some
antimicrobial peptides and other mem-
brane-active molecules, selective killing
of bacteria can be achieved by exploiting
themajor differences in the lipid composi-
tions between prokaryotic and mamma-
lian membranes (Hurdle et al., 2011;
Verkleij et al., 1973). These examples
therefore challenge the traditional view
that themembrane is an unsuitable target.
Thus, in this issue of Chemistry & Biology,
the study by Farha et al. (2013) is valiant
and against the mainstream dogma, in
that it seeks to prioritize rather than
eliminate membrane-active hit molecules.
This may well prompt revisiting such mol-
ecules that have been discarded because
they affect the bacterial membrane
properties.
In their strategy, Farha et al. (2013) opti-
mized the standard assay that adopts the
membrane-potential sensitive dye 3,5-
dipropylthiacarbocyanine [DISC3(5)] to
screen for molecules that either dissipate
the electrical potential (Dc) or the proton
gradient (DpH) of the S. aureusmembrane
(Figure 1). Paradoxically, DiSC3(5) assays
have been exploited by others to remove
membrane-active molecules (Gentry2013 Elsevier Ltd All rights reserved 1091
Figure 1. Screening and Preclinical Path for Hits Dissipating the Membrane’s Electrical
Potential—Dc—or Proton Gradient—DpH
The inset simplifies the membrane and respiratory chain as drug target sites; compounds are shown as
colored triangles; not shown is the peptidoglycan and unknownmembrane-embedded proteins that could
interact with membrane-active agents. The DiSC3(5) florescence data in the graph was derived from Farha
et al. (2013).
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Previewset al., 2010). Dc and DpH are the two
components of the cellular proton motive
force (PMF) that is intricate to bioener-
getics, solute transport, motility, and
maintenance of the intracellular pH for
protein function (Krulwich et al., 2011).
By screening a modest bioactive library
(30,000 compounds), the authors recov-
ered 72 compounds appearing as dissi-
pators of Dc and 272 compounds
appearing as dissipators of DpH. Impor-
tantly, follow-up dose response assays
and control assays were performed to
remove false hits that mimicked the
florescence of DiSC3(5) or quench its
florescence in a manner that was inde-
pendent of changes in the PMF. Conse-
quently, three hits were identified and
confirmed as specific dissipators of the
Dc and three as DpH dissipators. Most
of these hits only induced cytotoxicity at
concentrations above their minimum in-
hibitory concentration. Also, as expected,
combinations of Dc dissipators with DpH
dissipators were synergistic against
S. aureus, because this caused the com-
plete collapse of the PMF. Therefore, the
authors point to synergistic combinations
of Dc and DpH dissipators as a means of
dose sparing that lowers the cytotoxicity
of individual compounds while retaining
potency against bacteria (Farha et al.,1092 Chemistry & Biology 20, September 19,2013). Although this is a comprehensive
concept, its application to systemic
infections is challenged by the need to
match the pharmacology of the com-
pounds to achieve active drug in sufficient
concentrations at the site of infection. It
may more readily apply to treating topical
diseases such as staphylococcal skin in-
fections. It is also worth noting that
DiSC3(5) response assays do not provide
adequate insight to the biochemical or
molecular mechanism responsible for
perturbation of the membrane’s proper-
ties. Hence, suitable hits will need to un-
dergo detailed studies to understand
their action at the membrane target site.
For example, we only now understand
that the interaction of daptomycin with
the membrane does not only dissipate
Dc, but it also dramatically affects pepti-
doglycan biosynthesis and assembly of
cell division proteins (Pogliano et al.,
2012).
With the challenges of identifying anti-
biotic leads, the propensity of bacteria to
develop resistance, and the difficulty of
treating dormant bacterial infections,
membrane-active hits that are bacteri-
cidal and less prone to resistance selec-
tion may become more attractive. The
work by Farha et al. (2013) therefore en-
courages further debate on the utility of2013 ª2013 Elsevier Ltd All rights reservedmembrane-active hits. As this area ex-
pands, a number of pertinent questions
will need to be addressed to harness the
benefits of these types of molecules.
Certainly, it will be vital to address struc-
ture-activity relationships required to
attain selectivity and whether interaction
with prokaryote-specific components in
the cell envelope could render com-
pounds more selective. A need also
exists to extend this concept to Gram-
negative pathogens, for which there is a
desperate need for new antibiotics; we
speculate this will be most challenging
for lipophilic species that are precluded
from reaching the cytoplasmic mem-
brane by the lipopolysaccharide layer.
In closing, although chemical libraries
contain several nuisance compounds,
they also contain membrane-active mole-
cules, with some selectivity, which could
be polished by medicinal chemistry to
produce clinical candidates that could
be considered diamonds recovered from
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